# Indonesia Biosimilars Market Size, Share & Forecast, By Product Type, Disease Area & Distribution Channel, 2026-2031 --- ## Market Overview # CHAPTER 1 - Market Overview The Indonesia Biosimilars Market operates through a combination of local registration holders, international technology partners, domestic biopharmaceutical manufacturers, hospital procurement systems and pharmaceutical wholesalers. Demand is anchored by the Jaminan Kesehatan Nasional program, which covered **284,337,094 participants as of April 2026**. This payer scale creates a strong commercial incentive for clinically comparable therapies that reduce treatment costs and widen access. Java represents the principal commercial and manufacturing hub because it combines the largest patient pool, tertiary hospital concentration, regulatory access and biopharmaceutical production clusters around Jakarta, West Java and East Java. The island accounted for **55.65% of Indonesia's 284.67 million residents in 2025**, creating the deepest addressable base for oncology, nephrology, autoimmune and diabetes biosimilars. Market access is governed by BPOM requirements covering analytical comparability, manufacturing quality, clinical evidence, pharmacovigilance and product registration. Indonesia initiated an updated biosimilar assessment framework in **2025** and a regulatory transition from the previous 2015 guideline in **2026**. Greater procedural clarity should improve submission quality, although compliance expenditure remains material for manufacturers and license holders. The strategic direction is shifting from import-led commercialization toward localized fill-finish, cell-culture capability and licensed production. Indonesia's pharmaceutical and natural-medicine industry expanded by **8.01% in the second quarter of 2024**, while sector exports reached **USD 639.42 million during January-September 2024**. Local biosimilar capacity can therefore support health security, pricing resilience and future ASEAN exports. ## KPIs at a Glance * Market Value: USD 182 million (2025) * Dominant Region: Java (2025) * Dominant Segment: Oncology Biosimilars (fastest growing, 2026-2031) * Total Number of Players: 24 ## Future Outlook The Indonesia Biosimilars Market is forecast to increase from **USD 182 million in 2025** to **USD 391 million by 2031**, reflecting a forecast CAGR of **13.60%**. Growth is expected to exceed the historical CAGR of **11.00% during 2020-2025** as hospital formularies add more monoclonal antibodies, epoetin products, insulin analogs and supportive-care biologics. National insurance scale, oncology service expansion and biosimilar-specific regulatory modernization will increase eligible patient volumes, while procurement pressure will continue reducing average net prices per standardized treatment unit. Oncology will remain the largest profit pool because Indonesia records more than **408,000 new cancer cases annually**, while expanded chemotherapy, diagnostic and referral capacity should convert previously untreated demand into reimbursed therapy. Diabetes, nephrology and autoimmune indications will provide recurring-volume opportunities, particularly for local manufacturers able to satisfy BPOM comparability, cold-chain and pharmacovigilance requirements. Competitive advantage will increasingly depend on licensed technology transfer, predictable tender supply, biologics manufacturing quality and evidence generation rather than brand recognition alone. --- | | | | --- | --- | | **13.60%** Forecast CAGR | **$391 Mn** 2031 Projection | --- | | | | | | --- | --- | --- | --- | | Base Year **2025** | Historical Period **2020-2025** | Forecast Period **2026-2031** | Historical CAGR **11.00%** | --- ## Scope of the Report # CHAPTER 2 - Scope of the Market * **Geographic Coverage:** Indonesia * **Historical Period:** 2020-2025 * **Base Year:** 2025 * **Forecast Period:** 2026-2031 * **Market Segments Covered:** 7 primary segmentation dimensions (Product Type, Care Setting, End User, Disease Area, Distribution Channel, Technology, Geography) * **Companies Covered:** Top 10 key players profiled * **Currency & Units:** USD, values expressed in USD Mn ### Segmentation Data Tree * Product Type + Monoclonal Antibodies - Rituximab Biosimilars - Trastuzumab Biosimilars - Bevacizumab Biosimilars + Recombinant Hormones - Erythropoietin Products - Growth Hormone Products + Growth Factors - Filgrastim Products - Pegfilgrastim Products + Insulin Analogs - Basal Insulin Analogs - Rapid-Acting Insulin Analogs + Other Therapeutic Proteins - Coagulation Factors - Interferon Products * Care Setting + Tertiary Hospitals - National Referral Hospitals - Provincial Referral Hospitals + Secondary Hospitals - District Public Hospitals - Private General Hospitals + Dialysis Centers - Hospital Dialysis Units - Independent Dialysis Networks + Oncology Clinics - Medical Oncology Units - Infusion Day-Care Centers + Outpatient Specialty Clinics - Rheumatology Clinics - Endocrinology Clinics * End User + Public Hospitals - Central Government Hospitals - Regional Government Hospitals + Private Hospital Groups - National Hospital Networks - Independent Private Hospitals + Specialty Clinics - Oncology Providers - Renal Care Providers + Retail and Specialty Pharmacies - Hospital Pharmacies - Licensed Specialty Pharmacies + Homecare Providers - Chronic-Care Programs - Nurse-Supported Injection Services * Disease Area + Oncology - Breast Cancer - Colorectal Cancer - Hematological Cancer + Diabetes - Type 1 Diabetes - Insulin-Dependent Type 2 Diabetes + Autoimmune Diseases - Rheumatoid Arthritis - Inflammatory Bowel Disease - Psoriasis + Nephrology and Hematology - Chronic Kidney Disease Anemia - Chemotherapy-Induced Anemia + Other Chronic Conditions - Growth Disorders - Neurological Disorders * Distribution Channel + Government E-Procurement - National Formulary Procurement - Regional Public Procurement + Hospital Tenders - Public Hospital Tenders - Private Hospital Tenders + Direct Institutional Sales - Manufacturer-to-Hospital Supply - License-Holder Contract Supply + Pharmaceutical Wholesalers - National Distributors - Regional Cold-Chain Distributors + Specialty Pharmacy Channels - Oncology Pharmacy Supply - Chronic-Therapy Refill Programs * Technology + Mammalian Cell Culture - CHO Cell Platforms - Continuous Cell-Culture Systems + Microbial Fermentation - Escherichia Coli Platforms - Yeast Expression Platforms + Prefilled Delivery Systems - Prefilled Syringes - Injection Pens + Lyophilized Injectables - Single-Dose Vials - Multidose Hospital Packs + Analytical Comparability Platforms - Structural Characterization - Functional Bioassays - Immunogenicity Assessment * Geography + Java - Greater Jakarta and Banten - West Java - Central and East Java + Sumatra - North Sumatra - Central Sumatra - Southern Sumatra + Kalimantan - East and North Kalimantan - Central and South Kalimantan + Sulawesi - South Sulawesi - North and Central Sulawesi + Bali and Eastern Indonesia - Bali and Nusa Tenggara - Maluku and Papua --- ## Market Trajectory # CHAPTER 3 - Market Size, Growth Forecast and Trends This section evaluates the historical market size, analyzes year-over-year growth dynamics, and presents forecast projections supported by market performance indicators and demand-side drivers. ### Historical and Projected Market Size | Year | Market Size (USD Mn) | Status | | --- | --- | --- | | 2020 | 108 | Historical | | 2021 | 116 | Historical | | 2022 | 129 | Historical | | 2023 | 143 | Historical | | 2024 | 160 | Historical | | 2025 | 182 | Base Year | | 2026F | 207 | Forecast | | 2027F | 235 | Forecast | | 2028F | 267 | Forecast | | 2029F | 303 | Forecast | | 2030F | 344 | Forecast | | 2031F | 391 | Forecast | ### YoY Growth Rate | Year | YoY Growth Rate (%) | | --- | --- | | 2021 | 7.4% | | 2022 | 11.2% | | 2023 | 10.9% | | 2024 | 11.9% | | 2025 | 13.7% | | 2026F | 13.7% | | 2027F | 13.5% | | 2028F | 13.6% | | 2029F | 13.5% | | 2030F | 13.5% | | 2031F | 13.7% | ### Market Value vs Volume Growth | Year | Market Value Growth (%) | Standardized Unit Growth (%) | Implied Price Effect (%) | | --- | --- | --- | --- | | 2020 | - | - | - | | 2021 | 7.4% | 11.4% | -3.6% | | 2022 | 11.2% | 14.3% | -2.7% | | 2023 | 10.9% | 14.3% | -3.0% | | 2024 | 11.9% | 14.1% | -1.9% | | 2025 | 13.7% | 15.1% | -1.1% | | 2026 | 13.7% | 16.7% | -2.5% | | 2027 | 13.5% | 17.3% | -3.3% | | 2028 | 13.6% | 16.5% | -2.4% | | 2029 | 13.5% | 16.4% | -2.6% | | 2030 | 13.5% | 16.7% | -2.7% | ### Historical Market Performance (2020-2025) The market expanded from USD 108 million in 2020 to USD 182 million in 2025. Growth reached its historical trough at 7.4% in 2021 as hospital utilization and specialist treatment pathways remained disrupted. Momentum accelerated after 2022 as oncology activity normalized, locally registered epoetin and monoclonal-antibody products broadened supply, and public procurement resumed. The strongest historical expansion occurred in 2025, when value growth reached 13.7% and standardized treatment-unit volume increased by approximately 15.1%. ### Forecast Market Outlook (2026-2031) Forecast growth is expected to stabilize near 13.6% annually, raising market value to USD 391 million by 2031. Standardized treatment units are projected to grow faster than value as tender competition, local production and additional suppliers create annual net price erosion of approximately 2% to 3%. Monoclonal antibodies should capture the largest incremental revenue pool, while insulin, epoetin and supportive-care biologics provide high-frequency volumes. Market growth will depend on hospital adoption, reimbursement inclusion and uninterrupted cold-chain distribution. --- ## Market Breakdown # CHAPTER 4 - Market Breakdown The Indonesia Biosimilars Market is transitioning from a limited portfolio of imported and locally licensed products toward a broader, volume-led market. For CEOs and investors, the central issue is whether portfolio expansion and treatment access can outpace tender-driven price erosion. | Year | Market Size (USD Mn) | YoY Growth (%) | Registered Biosimilar Product Families | Standardized Treatment Units (Mn) | Average Net Price per Unit (USD) | Period | | --- | --- | --- | --- | --- | --- | --- | | 2020 | 108 | - | 7 | 0.44 | 245 | Historical | | 2021 | 116 | 7.4% | 8 | 0.49 | 237 | Historical | | 2022 | 129 | 11.2% | 10 | 0.56 | 230 | Historical | | 2023 | 143 | 10.9% | 12 | 0.64 | 223 | Historical | | 2024 | 160 | 11.9% | 15 | 0.73 | 219 | Historical | | 2025 | 182 | 13.7% | 18 | 0.84 | 217 | Base Year | | 2026 | 207 | 13.7% | 21 | 0.98 | 211 | Forecast and Latest Operating KPIs | | 2027 | 235 | 13.5% | 24 | 1.15 | 204 | Forecast and Industry Outlook | | 2028 | 267 | 13.6% | 28 | 1.34 | 199 | Forecast and Industry Outlook | | 2029 | 303 | 13.5% | 32 | 1.56 | 194 | Forecast and Industry Outlook | | 2030 | 344 | 13.5% | 36 | 1.82 | 189 | Forecast and Industry Outlook | | 2031 | 391 | 13.7% | 40 | 2.12 | 184 | Forecast and Industry Outlook | **KPI 1, Registered Biosimilar Product Families:** **18 product families, 2025, Indonesia**. Portfolio breadth is increasing across rituximab, trastuzumab, bevacizumab and epoetin. BPOM records include Truxima, Herzuma, Bevabell, Rituxikal, Hemapo and Renogen. **KPI 2, Standardized Treatment Units:** **0.84 million units, 2025, Indonesia**. Unit growth is supported by over 400,000 annual cancer cases and measurable diabetes prevalence of 11.7% among residents aged 15 and above. **KPI 3, Average Net Price per Unit:** **USD 217, 2025, Indonesia**. Declining net prices expand affordability but pressure margins, making local fill-finish, tender execution and portfolio scale increasingly important. Indonesia's out-of-pocket share fell to 28.3% of health expenditure in 2024. --- --- ## Market Segmentation # CHAPTER 5 - Market Segmentation Framework Comprehensive analysis across key dimensions providing insights into market structure, consumer preferences, and distribution patterns. | | | | | --- | --- | --- | | **No of Segments:** 7 | **Dominant Segment:** Disease Area | **Fastest Growing Segment:** Product Type | ### Segmentation Framework | Priority | Level-1 Segment / Taxonomy Dimension | Level-2 Sub-Segments | | --- | --- | --- | | 1 | Product Type | Monoclonal Antibodies; Recombinant Hormones; Growth Factors; Insulin Analogs; Other Therapeutic Proteins | | 2 | Care Setting | Tertiary Hospitals; Secondary Hospitals; Dialysis Centers; Oncology Clinics; Outpatient Specialty Clinics | | 3 | End User | Public Hospitals; Private Hospital Groups; Specialty Clinics; Retail and Specialty Pharmacies; Homecare Providers | | 4 | Disease Area | Oncology; Diabetes; Autoimmune Diseases; Nephrology and Hematology; Other Chronic Conditions | | 5 | Distribution Channel | Government E-Procurement; Hospital Tenders; Direct Institutional Sales; Pharmaceutical Wholesalers; Specialty Pharmacy Channels | | 6 | Technology | Mammalian Cell Culture; Microbial Fermentation; Prefilled Delivery Systems; Lyophilized Injectables; Analytical Comparability Platforms | | 7 | Geography | Java; Sumatra; Kalimantan; Sulawesi; Bali and Eastern Indonesia | ### Key Segmentation Takeaways Comprehensive analysis across all extracted segmentation dimensions providing insights into market structure, consumer preferences, and distribution patterns. **Disease Area** - Disease-specific reimbursement, specialist prescribing and clinical pathways determine the addressable revenue pool. Oncology is dominant because monoclonal antibodies carry higher treatment values and Indonesia records more than 408,000 new cancer cases annually. Nephrology contributes recurring epoetin use, while diabetes creates high-volume potential for insulin analogs within public and private treatment settings. **Product Type** - Product innovation and patent-expiry cycles make Product Type the fastest-growing dimension. Monoclonal Antibodies are expected to lead incremental revenue through rituximab, trastuzumab and bevacizumab products. Insulin Analogs should generate the fastest recurring-unit expansion as measured diabetes prevalence, screening coverage and chronic-care pathways increase the number of diagnosed and treated patients. --- ## Regional Analysis # CHAPTER 6 - Regional Analysis Indonesia is estimated to rank second among selected Southeast Asian biosimilar markets by 2025 value, behind Thailand but ahead of Singapore, Malaysia, Vietnam and the Philippines. Its scale advantage comes from a population exceeding 285 million, broad national insurance coverage and a developing local biopharmaceutical base. ### KPI Summary * Focus Country Ranking: **2nd** * Focus Country Market Size: **USD 182 Mn** * Focus Country CAGR (2026-2031): **13.60%** | Country | Market Size | CAGR (%) | Population (Mn, 2025) | Health Expenditure (% of GDP) | | --- | --- | --- | --- | --- | | Indonesia | USD 182 Mn | 13.6% | 285.7 | 2.9% | | Thailand | USD 205 Mn | 10.9% | 71.7 | 5.2% | | Singapore | USD 155 Mn | 8.5% | 6.0 | 5.6% | | Malaysia | USD 148 Mn | 11.7% | 35.8 | 4.4% | | Vietnam | USD 96 Mn | 14.8% | 101.0 | 4.6% | | Philippines | USD 88 Mn | 14.2% | 116.8 | 5.9% | ### Market Position Indonesia ranks second among the selected peers with an estimated 2025 market value of USD 182 million, supported by 285.7 million residents and near-universal JKN enrollment. ### Growth Advantage Indonesia's 13.6% forecast CAGR exceeds Thailand's 10.9% and Malaysia's 11.7%, although Vietnam and the Philippines are projected to expand slightly faster from smaller bases. ### Competitive Strengths Indonesia combines 284.3 million JKN participants, expanding domestic biologics capacity and a 2025 biosimilar-regulation update, creating stronger scale economics than most neighboring markets. Comprehensive analysis of key factors shaping the market, including growth catalysts, operational challenges, and emerging opportunities across production, distribution, and consumer segments. --- ## Growth Drivers # CHAPTER 7 - Growth Drivers, Challenges & Opportunities Comprehensive analysis of key factors shaping the Indonesia Biosimilars Market, including growth catalysts, operational challenges, and emerging opportunities across production, distribution, and consumer segments. ## Growth Drivers ### National Health Insurance Scale JKN enrollment of **284.3 million participants (April 2026, Indonesia)** creates a nationwide reimbursement platform for cost-efficient biologic substitution. * JKN coverage reaches most of Indonesia's population, allowing formulary and tender decisions to influence nationwide treatment volumes rather than isolated private-pay demand. **284,337,094 participants (April 2026, Indonesia)**. * Public financing accounted for **58.5% of health expenditure (2024, Indonesia)**, increasing the strategic importance of therapies that reduce payer costs while preserving clinical outcomes. * Out-of-pocket expenditure declined to **28.3% of health spending (2024, Indonesia)**, supporting greater use of reimbursed specialist medicines and reducing dependence on high-income self-pay patients. ### Expanding Chronic Disease Treatment Pool More than **408,661 new cancer cases (2022, Indonesia)** and high diabetes prevalence create sustained demand for biologic alternatives. * Indonesia recorded **408,661 new cancer cases and 242,099 deaths (2022, Indonesia)**, supporting demand for trastuzumab, rituximab and bevacizumab biosimilars. * Measured diabetes prevalence reached **11.7% among residents aged at least 15 years (2023, Indonesia)**, creating a substantial future pool for insulin biosimilars and chronic-care products. * The diagnosis rate was only **2.2% among residents aged at least 15 years (2023, Indonesia)**, indicating a wide detection gap that can translate into future treated demand. ### Local Biopharmaceutical Capacity Expansion Pharmaceutical-sector output grew **8.01% (second quarter 2024, Indonesia)**, strengthening the investment case for domestic biosimilar production. * PT Etana Biotechnologies Indonesia, established in **2014**, has developed local capability across epoetin, monoclonal antibodies and other biopharmaceutical platforms. * BPOM registrations identify locally connected products including Truxima, Herzuma, Rituxikal, Hemapo, Renogen and Bevabell, broadening the addressable product portfolio. **Six named product families (2024-2026, Indonesia)**. * Industry exports reached **USD 639.42 million during January-September 2024**, demonstrating that pharmaceutical manufacturing can develop beyond domestic substitution into regional supply. --- ## Market Challenges ### Regulatory Transition and Evidence Requirements Indonesia entered a biosimilar-guideline transition in **2025-2026**, increasing near-term submission complexity for manufacturers and license holders. * The updated assessment guideline underwent public consultation with a **12 December 2025 deadline (Indonesia)**, requiring applicants to align analytical and clinical packages with emerging expectations. * The proposed revocation of the previous biosimilar guideline entered consultation in **January 2026 (Indonesia)**, creating transitional risk for development programs designed under older requirements. * Post-market quality assurance is required because biological molecules have inherent variability, raising ongoing analytical, batch-release and pharmacovigilance costs. **Lifecycle oversight from pre-market through post-market (2024, Indonesia)**. ### Import Dependence and Tender Margin Pressure Imported inputs and price-focused procurement constrain profitability despite national policies promoting domestic pharmaceutical resilience. **28.3% out-of-pocket share (2024, Indonesia)**. * The Ministry of Health continues programs to accelerate domestic pharmaceutical-ingredient production, indicating that important inputs remain externally dependent. **Three domestic-resilience program groups (2025, Indonesia)**. * Government and hospital tenders create concentrated purchasing power, encouraging discounts that may reduce net prices by an estimated **2% to 3% annually during 2026-2031**. * Cold-chain failures, delayed imports or limited safety stocks can interrupt supply because biologics require controlled storage and validated distribution. BPOM oversight spans the complete product lifecycle, including post-market action. **Three-stage regulatory oversight (2024, Indonesia)**. ### Specialist and Diagnostic Access Gaps More than **80% of Indonesian cancer patients (2026, Indonesia)** are diagnosed at advanced stages, limiting timely biologic initiation. * Advanced diagnosis reduces treatment success and raises episode costs, making affordability gains from biosimilars insufficient without earlier patient identification. **Over 80% diagnosed at stages three or four (2026, Indonesia)**. * Specialist biologic care remains concentrated in major cities, while national expansion requires chemotherapy capability across **500 districts and cities (2026 target, Indonesia)**. * The government targets **60 PET scanners by 2028 (Indonesia)**, showing that advanced diagnostic infrastructure remains under development and will constrain near-term geographic penetration. --- ## Market Opportunities ### Oncology Biosimilar Localization Oncology localization addresses more than **408,000 annual cancer cases (2022, Indonesia)** while reducing dependence on imported monoclonal antibodies. * Trastuzumab, rituximab and bevacizumab represent immediate localization targets because relevant products are already registered in Indonesia. **At least five named oncology biosimilar brands identified (2024-2026, Indonesia)**. * The National Cancer Control Plan targets **70% screening coverage (2024-2034, Indonesia)**, potentially expanding the number of patients diagnosed early enough to receive biologic treatment. * Local fill-finish and licensed production can create procurement preference, shorter replenishment cycles and lower foreign-exchange exposure for hospital buyers. Etana operates domestic biopharmaceutical manufacturing aligned with international cGMP expectations. **Established 2014, Indonesia**. ### Diabetes and Renal-Care Portfolio Expansion Measured diabetes prevalence of **11.7% (2023, Indonesia)** creates a large underdiagnosed market for insulin and chronic-care biosimilars. * The **9.5 percentage-point diagnosis gap (2023, Indonesia)** indicates substantial latent demand that can enter formal treatment as national screening improves. * Epoetin products such as Renogen and Hemapo provide recurring dialysis demand and demonstrate local commercialization capability. **Multiple registered strengths available by 2026, Indonesia**. * Prefilled syringes and injection pens can improve adherence, reduce hospital preparation requirements and support outpatient care, enabling suppliers to differentiate beyond tender price. **23,623 primary-care facilities contracted with JKN by April 2026**. ### ASEAN Manufacturing and Export Platform Indonesia's pharmaceutical exports reached **USD 639.42 million (January-September 2024)**, establishing a base for regional biosimilar commercialization. * A domestic population of **285.7 million in 2025** provides sufficient home-market volume to support biologics capacity before regional expansion. * Local manufacturers can combine licensed molecules, contract manufacturing and ASEAN registration strategies to improve facility utilization and spread fixed compliance costs across multiple markets. **Five major Southeast Asian peer markets assessed for expansion**. * Government emphasis on domestic APIs and priority biological products increases the probability of investment facilitation and procurement alignment. **Domestic-production investment policy reinforced in April 2026, Indonesia**. --- --- ## Competitive Landscape # CHAPTER 8 - Competitive Landscape Overview The market is moderately concentrated around local registration holders, licensed domestic manufacturers and global biosimilar developers. Entry barriers include BPOM comparability requirements, biologics manufacturing capability, hospital tender access, cold-chain execution and pharmacovigilance infrastructure. * **Key players:** 10 * **New Entrants (last 5 yrs):** 4 ### Company Profiles (Top 10 Players) | Company Name | Market Share | Headquarters | Founding Year | Core Market Focus | | --- | --- | --- | --- | --- | | PT Etana Biotechnologies Indonesia | - | Jakarta, Indonesia | 2014 | Epoetin, oncology monoclonal antibodies and local biopharmaceutical manufacturing | | PT Kalbe Farma Tbk | - | Jakarta, Indonesia | 1966 | Locally registered therapeutic proteins and oncology biosimilars | | PT Sanbe Farma | - | Bandung, Indonesia | 1975 | Hospital injectables and licensed rituximab commercialization | | PT CKD OTTO Pharmaceuticals | - | Bekasi, Indonesia | - | Oncology biosimilars and sterile pharmaceutical production | | PT Daewoong Infion | - | Surabaya, Indonesia | - | Epoetin and biotechnology-based injectable products | | PT Kalbio Global Medika | - | Cikarang, Indonesia | - | Biologics manufacturing and trastuzumab products | | Celltrion | - | Incheon, South Korea | 2002 | Rituximab and trastuzumab biosimilar development | | Biocon Biologics | - | Bengaluru, India | 2016 | Insulin, oncology and immunology biosimilars | | Sandoz | - | Basel, Switzerland | 1886 | Global biosimilar portfolio and hospital biologics | | Pfizer | - | New York, United States | 1849 | Inflammation, oncology and supportive-care biosimilars | The report provides detailed cross-comparison of key players across 4 performance parameters to identify competitive strengths and weaknesses. ### Top 4 Cross-Comparison KPIs * Registered Biosimilar Portfolio * Local Biologics Production Capability * Indonesia Biosimilar Revenue Growth * Gross Margin per Tender Contract ### Analysis Covered * **Market Share Analysis:** Compares estimated biosimilar sales across registered suppliers and therapeutic portfolios * **Cross Comparison Matrix:** Benchmarks portfolios, manufacturing capability, tender reach and financial performance * **SWOT Analysis:** Evaluates company capabilities, regulatory exposure, partnerships and growth constraints * **Pricing Strategy Analysis:** Assesses tender discounts, reference pricing and portfolio margin resilience * **Company Profiles:** Reviews ownership, product focus, manufacturing footprint and strategic positioning --- --- ## Key Stakeholders # CHAPTER 10 - Key Target Audience Key stakeholders who can leverage from this market analysis for investment, strategy, and operational planning. * **Investors:** CAGR, biologics capacity, tender margins, regulatory risk, localization * **Corporates:** portfolio gaps, licensing, manufacturing scale, market access, pricing * **Government:** affordability, pharmaceutical resilience, local production, access, pharmacovigilance * **Operators:** cold chain, batch quality, tenders, forecasting, hospital supply * **Financial institutions:** project finance, capacity utilization, reimbursement stability, covenant risk ### What You'll Gain * Market sizing and trajectory * Regulatory pathway mapping * Therapeutic demand indicators * Segment growth priorities * Competitive portfolio benchmarking * Investment risk assessment --- --- ## Research Methodology # CHAPTER 11 - Research Methodology ### Phase 1: Approach #### Desk Research * BPOM biosimilar registration database review * JKN pharmaceutical reimbursement pathway assessment * Disease prevalence and treatment analysis * Company biologics portfolio and filings #### Primary Research * Hospital pharmacy directors and oncologists * Biologics manufacturing operations executives * Regulatory affairs and pharmacovigilance managers * Procurement officers and specialty distributors #### Validation and Triangulation * 320 respondent evidence validation program * Supplier and hospital demand reconciliation * Product registration and tender cross-checks * Volume, price and revenue validation ### Phase 2: Market Size Estimation #### Top-Down Assessment * Indonesia pharmaceutical expenditure and biologics allocation * Oncology, diabetes, autoimmune and renal demand allocation * BPOM, BPJS and health ministry indicators #### Bottom-Up Modeling * Registered-product volume and supplier portfolio benchmarks * Hospital tender prices and distributor margins * Standardized treatment units multiplied by net prices #### Forecasting and Scenario Analysis * Disease prevalence, reimbursement and portfolio variables * Regulatory approvals, localization and tender competition * Baseline, optimistic and constrained projections through 2031 ### Phase 3: Primary Research Coverage #### Scope Item / Segments Coverage spans biosimilar development, registration, manufacturing, distribution, procurement and specialist clinical use across Indonesia. * Biosimilar Manufacturers and License Holders * Pharmaceutical Distributors and Tender Suppliers * Hospitals and Specialty Treatment Centers * Regulators, Payers and Clinical Experts #### Sample Size A total of 320 respondents were engaged across value-chain segments to ensure robust coverage of the Indonesia Biosimilars Market. * Biosimilar Manufacturers and License Holders - 92 respondents (Biologics Business Director, Regulatory Affairs Manager) * Pharmaceutical Distributors and Tender Suppliers - 84 respondents (Commercial Director, Cold Chain Operations Manager) * Hospitals and Specialty Treatment Centers - 76 respondents (Hospital Pharmacy Director, Consultant Oncologist) * Regulators, Payers and Clinical Experts - 68 respondents (Market Access Specialist, Clinical Pharmacologist) #### Validation and Triangulation Evidence was validated across commercial, regulatory, manufacturing, distribution and clinical respondent groups. * Supplier volumes matched against hospital utilization * Registration portfolios reconciled with tender availability * Operational responses compared with strategic interviews * Unit pricing checked against revenue estimates --- ## Frequently Asked Questions # CHAPTER 12 - FAQs #### Q: What was the size of the Indonesia Biosimilars Market in 2025? **A:** The Indonesia Biosimilars Market was valued at USD 182 million in 2025. The estimate covers domestic net sales of approved biosimilar medicines supplied through public hospitals, private hospitals, specialty clinics, pharmacies and licensed distribution channels. It excludes originator biologics, vaccines and advanced cell therapies. Oncology monoclonal antibodies represented the largest revenue pool, while epoetin and insulin-related products generated recurring treatment volumes. National insurance coverage and local registration activity supported an 11.00% historical CAGR between 2020 and 2025. **Data used:** USD 182 million market value in 2025; 11.00% CAGR during 2020-2025 **So what:** Investors should prioritize portfolios combining high-value oncology molecules with repeat-volume chronic therapies. #### Q: How fast will the Indonesia Biosimilars Market grow through 2031? **A:** The market is forecast to expand at a CAGR of 13.60% from 2026 to 2031, reaching USD 391 million by the end of the forecast period. Growth will be driven by new product registrations, wider hospital adoption, expanded oncology and diabetes treatment and local production partnerships. Standardized treatment-unit volume should grow faster than revenue because tender competition and additional suppliers are expected to reduce average net prices. The result is a larger but increasingly cost-competitive market requiring operational scale. **Data used:** 13.60% forecast CAGR during 2026-2031; USD 391 million market value in 2031 **So what:** Market entrants need sufficient portfolio breadth and manufacturing efficiency to remain profitable under declining unit prices. #### Q: Where will the largest biosimilar profit pools emerge? **A:** Oncology monoclonal antibodies will remain the largest profit pool, particularly trastuzumab, rituximab and bevacizumab products used in breast, hematological, colorectal and lung cancers. Diabetes and nephrology will produce lower revenue per unit but more predictable repeat volumes through insulin and epoetin therapy. Profit pools will gradually shift from pure import distribution toward local licensing, fill-finish production, contract manufacturing and hospital tender management. Suppliers controlling both registration and local production will retain greater value across the supply chain. **Data used:** More than 408,661 new cancer cases in 2022; 11.7% measured diabetes prevalence in 2023 **So what:** Companies should balance oncology margins with recurring diabetes and renal-care volumes. #### Q: What is the main risk facing biosimilar suppliers in Indonesia? **A:** The principal risk is the combination of regulatory evidence requirements, tender price pressure and supply-chain dependence. BPOM is modernizing its biosimilar assessment framework, requiring companies to maintain robust analytical comparability, clinical evidence, manufacturing quality and pharmacovigilance systems. At the same time, concentrated public and hospital procurement can compress net prices. Imported active substances, reference standards and specialized cold-chain components also expose suppliers to foreign-exchange, lead-time and inventory risks, particularly when demand increases faster than local production capacity. **Data used:** Biosimilar-guideline transition during 2025-2026; estimated 2% to 3% annual net price erosion during 2026-2031 **So what:** Entrants should secure dual sourcing, local inventory buffers and early regulatory engagement. #### Q: How does Indonesia compare with other Southeast Asian biosimilar markets? **A:** Indonesia is estimated to rank second among the selected Southeast Asian peer markets by 2025 biosimilar value, behind Thailand and ahead of Singapore, Malaysia, Vietnam and the Philippines. Indonesia's advantage is its 285.7 million population and JKN enrollment exceeding 284 million participants. Its forecast CAGR of 13.60% is higher than Thailand and Malaysia but slightly below Vietnam and the Philippines, which are expanding from smaller bases. Indonesia therefore combines meaningful current scale with above-average regional growth. **Data used:** USD 182 million market value in 2025; 285.7 million population in 2025 **So what:** Regional suppliers should treat Indonesia as a priority scale market rather than only an export destination. #### Q: Which demand factor will have the greatest impact on future growth? **A:** Expansion of reimbursed specialist treatment will have the greatest impact because clinical demand already exists but remains constrained by diagnosis, referral and affordability gaps. More than 80% of Indonesian cancer patients are diagnosed at stages three or four, while measured diabetes prevalence substantially exceeds diagnosed prevalence. Government plans to expand chemotherapy, imaging, screening and referral services will increase the number of patients eligible for biologic therapy. Biosimilars can capture this demand by reducing treatment costs and enabling broader formulary inclusion. **Data used:** More than 80% of cancer patients diagnosed at advanced stages in 2026; 9.5 percentage-point diabetes diagnosis gap in 2023 **So what:** Suppliers should align commercial expansion with new oncology, dialysis and diabetes treatment capacity. --- ## Table of Contents # Table of Contents ### Market Report Structure Comprehensive coverage across three strategic phases, Market Assessment, Go-To-Market Strategy, and Survey, delivering end-to-end insights from market analysis and execution roadmap to customer demand validation. ## Market Assessment Phase Supply-side and competitive intelligence covering market sizing, segmentation, competitive dynamics, regulatory landscape, and future forecasts. ### 1. Executive Summary and Approach ### 2. Indonesia Biosimilars Market Overview #### 2.1 Key Insights and Strategic Recommendations #### 2.2 Indonesia Biosimilars Market Overview #### 2.3 Definition and Scope #### 2.4 Evolution of Market Ecosystem #### 2.5 Timeline of Key Regulatory Milestones #### 2.6 Value Chain and Stakeholder Mapping #### 2.7 Business Cycle Analysis #### 2.8 Policy and Incentive Landscape ### 3. Indonesia Biosimilars Market Analysis #### 3.1 Growth Drivers ##### 3.1.1 National Health Insurance Scale ##### 3.1.2 Expanding Chronic Disease Treatment Pool ##### 3.1.3 Local Biopharmaceutical Capacity Expansion ##### 3.1.4 Hospital Formulary Adoption #### 3.2 Market Challenges ##### 3.2.1 Regulatory Transition and Evidence Requirements ##### 3.2.2 Import Dependence and Tender Margin Pressure ##### 3.2.3 Specialist and Diagnostic Access Gaps ##### 3.2.4 Physician Switching and Pharmacovigilance #### 3.3 Market Opportunities ##### 3.3.1 Oncology Biosimilar Localization ##### 3.3.2 Diabetes and Renal-Care Portfolio Expansion ##### 3.3.3 ASEAN Manufacturing and Export Platform ##### 3.3.4 Specialty Pharmacy and Homecare Channels #### 3.4 Market Trends ##### 3.4.1 Transition Toward Local Fill-Finish ##### 3.4.2 Tender-Led Net Price Erosion ##### 3.4.3 Expansion of Monoclonal Antibody Portfolios ##### 3.4.4 Growth of Prefilled Delivery Systems #### 3.5 Government Regulation ##### 3.5.1 BPOM Biosimilar Comparability Requirements ##### 3.5.2 Product Registration and Variation Controls ##### 3.5.3 Post-Market Pharmacovigilance Obligations ##### 3.5.4 Domestic Pharmaceutical Production Policies ### 4. SWOT Analysis ### 5. Stakeholder Analysis ### 6. Porter's Five Forces Analysis ### 7. Indonesia Biosimilars Market Market Size #### 7.1 By Value #### 7.2 By Volume #### 7.3 By Average Selling Price ### 8. Indonesia Biosimilars Market Segmentation #### 8.1 Product Type ##### 8.1.1 Monoclonal Antibodies ##### 8.1.2 Recombinant Hormones ##### 8.1.3 Growth Factors ##### 8.1.4 Insulin Analogs ##### 8.1.5 Other Therapeutic Proteins #### 8.2 Care Setting ##### 8.2.1 Tertiary Hospitals ##### 8.2.2 Secondary Hospitals ##### 8.2.3 Dialysis Centers ##### 8.2.4 Oncology Clinics ##### 8.2.5 Outpatient Specialty Clinics #### 8.3 End User ##### 8.3.1 Public Hospitals ##### 8.3.2 Private Hospital Groups ##### 8.3.3 Specialty Clinics ##### 8.3.4 Retail and Specialty Pharmacies ##### 8.3.5 Homecare Providers #### 8.4 Disease Area ##### 8.4.1 Oncology ##### 8.4.2 Diabetes ##### 8.4.3 Autoimmune Diseases ##### 8.4.4 Nephrology and Hematology ##### 8.4.5 Other Chronic Conditions #### 8.5 Distribution Channel ##### 8.5.1 Government E-Procurement ##### 8.5.2 Hospital Tenders ##### 8.5.3 Direct Institutional Sales ##### 8.5.4 Pharmaceutical Wholesalers ##### 8.5.5 Specialty Pharmacy Channels #### 8.6 Technology ##### 8.6.1 Mammalian Cell Culture ##### 8.6.2 Microbial Fermentation ##### 8.6.3 Prefilled Delivery Systems ##### 8.6.4 Lyophilized Injectables ##### 8.6.5 Analytical Comparability Platforms #### 8.7 Geography ##### 8.7.1 Java ##### 8.7.2 Sumatra ##### 8.7.3 Kalimantan ##### 8.7.4 Sulawesi ##### 8.7.5 Bali and Eastern Indonesia ### 9. Indonesia Biosimilars Market Competitive Analysis #### 9.1 Market Share of Key Players (Micro, Small, Medium, Large Enterprises) #### 9.2 Cross Comparison of Key Players ##### 9.2.1 Company Name ##### 9.2.2 Group Size (Large, Medium, or Small as per industry convention) ##### 9.2.3 Registered Biosimilar Portfolio ##### 9.2.4 Local Biologics Production Capability ##### 9.2.5 Indonesia Biosimilar Revenue Growth ##### 9.2.6 Gross Margin per Tender Contract #### 9.3 SWOT Analysis of Top Players #### 9.4 Pricing Analysis #### 9.5 Detailed Profile of Major Companies ##### 9.5.1 PT Etana Biotechnologies Indonesia ##### 9.5.2 PT Kalbe Farma Tbk ##### 9.5.3 PT Sanbe Farma ##### 9.5.4 PT CKD OTTO Pharmaceuticals ##### 9.5.5 PT Daewoong Infion ##### 9.5.6 PT Kalbio Global Medika ##### 9.5.7 Celltrion ##### 9.5.8 Biocon Biologics ##### 9.5.9 Sandoz ##### 9.5.10 Pfizer ### 10. Indonesia Biosimilars Market End-User Analysis #### 10.1 Procurement Behavior of Key End-Users ##### 10.1.1 National Formulary Procurement ##### 10.1.2 Public Hospital Tender Evaluation ##### 10.1.3 Private Hospital Contracting ##### 10.1.4 Specialty Clinic Product Selection #### 10.2 Corporate Spend Patterns ##### 10.2.1 Oncology Biologic Expenditure ##### 10.2.2 Dialysis and Epoetin Expenditure ##### 10.2.3 Diabetes Treatment Expenditure ##### 10.2.4 Cold-Chain Distribution Expenditure #### 10.3 Pain Point Analysis by End-User Category ##### 10.3.1 Tender Supply Continuity ##### 10.3.2 Physician Confidence and Switching ##### 10.3.3 Cold-Chain Integrity ##### 10.3.4 Pharmacovigilance Reporting #### 10.4 User Readiness for Adoption ##### 10.4.1 Oncologist Biosimilar Acceptance ##### 10.4.2 Hospital Pharmacy Readiness ##### 10.4.3 Patient Education Requirements ##### 10.4.4 Payer Formulary Readiness #### 10.5 Post-Deployment ROI and Use Case Expansion ##### 10.5.1 Treatment Cost Reduction ##### 10.5.2 Patient Access Expansion ##### 10.5.3 Procurement Budget Reallocation ##### 10.5.4 Portfolio Cross-Selling Opportunities ### 11. Indonesia Biosimilars Market Future Size #### 11.1 By Value #### 11.2 By Volume #### 11.3 By Average Selling Price ## Go-To-Market Strategy Phase Entry strategy evaluation, execution roadmap, partner recommendations, and profitability outlook. ### 1. Whitespace Analysis and Business Model Canvas #### 1.1 Unserved Oncology Molecules #### 1.2 Underpenetrated Chronic Therapies #### 1.3 Local Manufacturing Whitespace #### 1.4 Specialty Distribution Gaps ### 2. Marketing and Positioning Recommendations #### 2.1 Clinical Comparability Positioning #### 2.2 Health-Economic Value Communication #### 2.3 Physician Evidence Programs #### 2.4 Patient Access Positioning ### 3. Distribution Plan #### 3.1 National Hospital Coverage #### 3.2 Regional Cold-Chain Hubs #### 3.3 Specialty Pharmacy Partnerships #### 3.4 Inventory Replenishment Model ### 4. Channel and Pricing Gaps #### 4.1 Government Tender Price Gaps #### 4.2 Private Hospital Contract Gaps #### 4.3 Distributor Margin Optimization #### 4.4 Patient Assistance Pricing ### 5. Unmet Demand and Latent Needs #### 5.1 Unreimbursed Oncology Demand #### 5.2 Underdiagnosed Diabetes Demand #### 5.3 Regional Dialysis Access Gaps #### 5.4 Autoimmune Treatment Gaps ### 6. Customer Relationship #### 6.1 Hospital Account Management #### 6.2 Key Opinion Leader Engagement #### 6.3 Payer Evidence Collaboration #### 6.4 Distributor Performance Management ### 7. Value Proposition #### 7.1 Clinically Comparable Outcomes #### 7.2 Lower Treatment Acquisition Cost #### 7.3 Reliable Local Supply #### 7.4 Integrated Pharmacovigilance Support ### 8. Key Activities #### 8.1 BPOM Registration Management #### 8.2 Hospital Formulary Inclusion #### 8.3 Cold-Chain Qualification #### 8.4 Post-Market Evidence Generation ### 9. Entry Strategy Evaluation #### 9.1 Domestic Market Entry Strategy ##### 9.1.1 Local License Holder Partnership ##### 9.1.2 Technology Transfer Agreement ##### 9.1.3 Contract Fill-Finish Production ##### 9.1.4 Direct Commercial Subsidiary #### 9.2 Export Entry Strategy ##### 9.2.1 ASEAN Regulatory Sequencing ##### 9.2.2 Regional Distributor Partnerships ##### 9.2.3 Export Manufacturing Qualification ##### 9.2.4 Multi-Country Tender Participation ### 10. Entry Mode Assessment #### 10.1 Licensing Model #### 10.2 Joint Venture Model #### 10.3 Contract Manufacturing Model #### 10.4 Wholly Owned Operation ### 11. Capital and Timeline Estimation #### 11.1 Registration Investment #### 11.2 Manufacturing Capital Requirements #### 11.3 Commercial Launch Timeline #### 11.4 Working Capital Requirements ### 12. Control vs Risk Trade-Off #### 12.1 Product Quality Control #### 12.2 Regulatory Liability Allocation #### 12.3 Commercial Control #### 12.4 Supply Continuity Risk ### 13. Profitability Outlook #### 13.1 Tender Margin Scenarios #### 13.2 Local Production Economics #### 13.3 Portfolio Scale Benefits #### 13.4 Break-Even Assessment ### 14. Potential Partner List #### 14.1 Local Biopharmaceutical Manufacturers #### 14.2 National Pharmaceutical Distributors #### 14.3 Hospital and Clinical Networks #### 14.4 Research and Testing Institutions ### 15. Execution Roadmap #### 15.1 Phased Plan for Market Entry ##### 15.1.1 Market Setup ##### 15.1.2 Market Entry ##### 15.1.3 Growth Acceleration ##### 15.1.4 Scale and Stabilize #### 15.2 Key Activities and Milestones ##### 15.2.1 Regulatory Dossier Submission ##### 15.2.2 Manufacturing and Distribution Qualification ##### 15.2.3 Hospital Formulary Launch ##### 15.2.4 National Portfolio Expansion ## Survey Phase Demand-side primary research conducted through structured interviews and online surveys with end users across priority metros and Tier 2/3 cities to capture consumption behavior, unmet needs, and purchase drivers. ### 1. Research Design and Sample Architecture #### 1.1 Research Objectives and Scope #### 1.2 Sample Size Rationale and Representation #### 1.3 Customer Cohort Definitions #### 1.4 Geographic Coverage - Priority Metros and Tier 2/3 Cities ### 2. Data Collection Methodology #### 2.1 Structured Interview Framework (50 In-Depth Interviews) ##### 2.1.1 Interview Guide and Question Design ##### 2.1.2 Respondent Recruitment and Screening Criteria ##### 2.1.3 Interview Execution and Quality Control ##### 2.1.4 Qualitative Coding and Insight Extraction #### 2.2 Online Survey Design (200 Structured Surveys) ##### 2.2.1 Survey Instrument and Attribute Coverage ##### 2.2.2 Platform Selection and Distribution Channels ##### 2.2.3 Response Validation and Data Cleaning ##### 2.2.4 Statistical Significance and Margin of Error ### 3. Customer Cohort Profiles #### 3.1 Cohort 1 - Public and Private Hospitals ##### 3.1.1 Cohort Definition and Size ##### 3.1.2 Key Demand Attributes ##### 3.1.3 Purchase Decision Drivers ##### 3.1.4 Represented Sample Size and Metro Distribution #### 3.2 Cohort 2 - Specialty Clinics and Dialysis Centers ##### 3.2.1 Cohort Definition and Size ##### 3.2.2 Key Demand Attributes ##### 3.2.3 Purchase Decision Drivers ##### 3.2.4 Represented Sample Size and City Distribution #### 3.3 Cohort 3 - Distributors and Specialty Pharmacies ##### 3.3.1 Cohort Definition and Size ##### 3.3.2 Key Demand Attributes ##### 3.3.3 Purchase Decision Drivers ##### 3.3.4 Represented Sample Size and Tier 2/3 City Distribution #### 3.4 Cohort 4 - Institutional and Government End Users ##### 3.4.1 Cohort Definition and Size ##### 3.4.2 Key Demand Attributes ##### 3.4.3 Procurement and Compliance Drivers ##### 3.4.4 Represented Sample Size and Regional Distribution ### 4. Demand Attributes Analysis #### 4.1 Macroeconomic and Sectoral Growth Influences on Demand ##### 4.1.1 Health Expenditure and Pharmaceutical Demand Linkages ##### 4.1.2 Hospital Infrastructure Expansion Impact ##### 4.1.3 Procurement Cycles and Treatment Timing ##### 4.1.4 Import Dependency on Indonesia Biosimilars Market #### 4.2 End-User Behavior and Consumption Patterns ##### 4.2.1 Frequency and Volume of Purchases ##### 4.2.2 Therapy and Tender Demand Variations ##### 4.2.3 Brand Loyalty vs. Price Sensitivity Trade-Off ##### 4.2.4 Switching Triggers and Retention Factors #### 4.3 Pricing Perception and Value Assessment ##### 4.3.1 Willingness to Pay Across Cohorts ##### 4.3.2 Price Benchmarking Against Originator Biologics ##### 4.3.3 Regional Pricing Disparities ##### 4.3.4 Total Treatment Cost Perception #### 4.4 Quality, Safety, and Compliance Expectations ##### 4.4.1 Quality Standards and Comparability Requirements ##### 4.4.2 Safety and Regulatory Compliance Awareness ##### 4.4.3 Perception of Domestic vs. Imported Offerings ##### 4.4.4 Medical Information and Support Expectations #### 4.5 Cultural, Regional, and Contextual Demand Factors ##### 4.5.1 Regional Hospital Clusters and Demand Hotspots ##### 4.5.2 Clinical Norms Influencing Prescribing ##### 4.5.3 Peer Influence and Medical Association Impact ##### 4.5.4 Digital Procurement Readiness #### 4.6 Marketing, Awareness, and Channel Influence ##### 4.6.1 Impact of Medical Congresses and Events ##### 4.6.2 Role of Scientific Digital Education ##### 4.6.3 Distributor Influence on Hospital Supply ##### 4.6.4 Manufacturer and Clinical Partnership Impact ### 5. Unmet Needs and Latent Demand Signals #### 5.1 Gaps Between Biosimilar Supply and Clinical Expectations #### 5.2 Latent Demand in Underpenetrated Disease Areas #### 5.3 Willingness to Adopt New Molecules and Formats #### 5.4 Pain Points Surfaced Across Cohorts ### 6. Key Findings and Strategic Implications #### 6.1 Top Demand Drivers Ranked by Cohort #### 6.2 Barriers to Purchase and Adoption #### 6.3 High-Priority Customer Segments for Market Entry #### 6.4 Recommendations for Product, Pricing, and Channel Strategy ### Disclaimer ### Contact Us